GlassScriptPhysician profile
Beth A Miller
NPI 1407500135
$2,743.54
in general payments reported to CMS, 2019-2025
21 companies · $768 in 2025
The $768 reported for 2025 was more than what 93% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $525 · 2023: $835 · 2024: $616 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.44 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $485.11 | 2022-2025 | Nexplanon, Nuvaring |
| Mayne Pharma Commercial LLC | $410.99 | 2023-2025 | |
| Hologic Sales and Service, LLC | $266.00 | 2022-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Astellas Pharma US INC | $249.49 | 2023-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $240.58 | 2022-2025 | |
| Exeltis, USA INC. | $238.93 | 2022-2025 | Slynd |
| Pfizer INC. | $123.67 | 2022-2025 | |
| Shield Therapeutics INC | $121.77 | 2023-2025 | Accrufer |
| Sage Therapeutics, LLC | $103.43 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $91.83 | 2025 | Myfembree |
| Alexion Pharmaceuticals, INC. | $70.71 | 2022-2023 | Ultomiris |
| Millicent US INC | $50.43 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Abbvie INC. | $47.87 | 2022-2023 | |
| Coopersurgical, INC. | $47.32 | 2025 | Paragard T 380a |
| Minerva Surgical, INC | $36.77 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.47 | 2022-2023 | Gardasil 9 |
| Pacira Pharmaceuticals Incorporated | $30.82 | 2023-2024 | Exparel |
| Amgen INC. | $28.79 | 2022-2024 | Prolia, Evenity |
| Myriad Women'S Health, INC. | $27.84 | 2023 | Myrisk |
| Myovant Sciences INC. | $24.37 | 2022 | |
| Exact Sciences Corporation | $14.35 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.